Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shenzhen YHLO Biotech CoSHSE:688575 +5.13%64 EV-to-EBITDA is 12.24 as of Sep. 21, 2026, which is 65% below its 10-year median of 34.52. GuruFocus rates SHSE:688575 with a GF Score™ of 64/100 and a GF Value™ of ¥15.87 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 532 Medical Devices & Instruments companies, Shenzhen YHLO Biotech Co ranks better than 53.95% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shenzhen YHLO Biotech Co's enterprise value is ¥6,123 Mil.
Shenzhen YHLO Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥500 Mil. Therefore, Shenzhen YHLO Biotech Co's EV-to-EBITDA for today is 12.24.
The historical rank and industry rank for Shenzhen YHLO Biotech Co's EV-to-EBITDA or its related term are showing as below:
SHSE:688575'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.21 Med: 34.52 Max: 94.54
Current: 12.24
During the past 8 years, the highest EV-to-EBITDA of Shenzhen YHLO Biotech Co was 94.54. The lowest was 8.21. And the median was 34.52.
SHSE:688575's EV-to-EBITDA is ranked better than 53.95% of 532
companies
in the Medical Devices & Instruments industry
Industry Median: 13.14
vs SHSE:688575: 12.24
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Shenzhen YHLO Biotech Co (SHSE:688575) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shenzhen YHLO Biotech Co's PE Ratio (TTM) for today is calculated as:
Shenzhen YHLO Biotech Co's share price for today is ¥10.24.
Shenzhen YHLO Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.118.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688575 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Shenzhen YHLO Biotech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen YHLO Biotech Co EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shenzhen YHLO Biotech Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shenzhen YHLO Biotech Co's EV-to-EBITDA falls into.
Shenzhen YHLO Biotech Co's current Enterprise Value is ¥6,123 Mil.
Shenzhen YHLO Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥500 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen YHLO Biotech Co (SHSE:688575) has a EV-to-EBITDA of 12.24 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shenzhen YHLO Biotech Co. This is 65% below median its historical median of 34.52. Over the past decade, Shenzhen YHLO Biotech Co's EV-to-EBITDA has ranged from 8.21 to 94.54. According to the industry distribution chart, Shenzhen YHLO Biotech Co ranks #245 out of 532 companies in the Medical Devices & Instruments industry, placing it in the top 46.1%.
Is Shenzhen YHLO Biotech Co's EV-to-EBITDA too high?
Shenzhen YHLO Biotech Co's current EV-to-EBITDA of 12.24 is 65% below median its 10-year median of 34.52. Over the past 10 years, this metric has ranged from a low of 8.21 to a high of 94.54. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.14. Shenzhen YHLO Biotech Co's value of 12.24 is 6.8% below this industry median. Based on the distribution chart, Shenzhen YHLO Biotech Co ranks #245 out of 532 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shenzhen YHLO Biotech Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen YHLO Biotech Co's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shenzhen YHLO Biotech Co ranks #245 out of 532 companies for EV-to-EBITDA. This puts Shenzhen YHLO Biotech Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.14. Shenzhen YHLO Biotech Co's value of 12.24 is 6.8% below this benchmark. Historically, Shenzhen YHLO Biotech Co's own EV-to-EBITDA has ranged from 8.21 to 94.54 over the past decade. While the company's 10-year median is 34.52 vs. the industry median of 13.14, Shenzhen YHLO Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.14, based on 532 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen YHLO Biotech Co's current EV-to-EBITDA of 12.24 is 6.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shenzhen YHLO Biotech Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen YHLO Biotech Co's current EV-to-EBITDA is 12.24, which is 65% below median its own 10-year median of 34.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen YHLO Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co (SHSE:688575) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥15.87, compared to a current price of ¥10.24 — trading 35.5% below its estimated fair value. The current EV-to-EBITDA is 12.24, which is 65% below median its 10-year median of 34.52 and 6.8% below the Medical Devices & Instruments industry median of 13.14. Shenzhen YHLO Biotech Co's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shenzhen YHLO Biotech Co (SHSE:688575), the current EV-to-EBITDA is 12.24 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen YHLO Biotech Co (SHSE:688575) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co stock appears to be undervalued.
The current stock price of ¥10.24 is trading 35.5% below its estimated GF Value™ of ¥15.87.
GuruFocus considers Shenzhen YHLO Biotech Co to be Significantly Undervalued.
Key valuation signals for SHSE:688575:
EV-to-EBITDA: 12.24 (65% below median its 10-year median of 34.52)
GF Value™: ¥15.87 vs. price of ¥10.24 (35.5% below fair value)
Industry Position: 6.8% below the Medical Devices & Instruments median (#245 of 532)
No single metric tells the full story. See the SHSE:688575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen YHLO Biotech Co Ltd is engaged in the research, development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay. Its product portfolio includes solutions based on technologies such as chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. Its products are used in diagnostic applications including autoimmunity, reproductive health, infection, liver disease, and respiratory disease testing, and are supplied to healthcare institutions and testing centers.
64GF Score
Get the complete analysis for SHSE:688575
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688575 has been successfully added to your 
